RxDoctor Payments Data

Michael Mihara, MD

Internal Medicine · Aiea, HINPI 1750324919

Payments from drug & device makers

$8,354in general payments, 2019–2025

Across 502 payments — averaging $16.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • Amarin Pharma, Inc.$919
  • Lilly USA, LLC$878
  • Boehringer Ingelheim$840
  • Novo Nordisk$721
  • AstraZeneca$675
  • plus $3K from 20 others

What the payments were for

  • Food & beverage$8,325100%
  • Education$290%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,354 in reported general payments places this provider in the 90th percentile of 655 internal medicine providers in Hawaii.

See all internal medicine providers in Hawaii

Medicare billing

Part B allowed, 2024
$105,507
Medicare patients
296
Services billed
1,142

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin53$94,768
JanuviaSitagliptin Phosphate36$58,329
TrulicityDulaglutide43$55,423
RybelsusSemaglutide22$51,151
OzempicSemaglutide29$41,936
EliquisApixaban19$25,421
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$22,189
Atorvastatin Calcium402$12,944
Rosuvastatin Calcium215$8,869
Olmesartan Medoxomil112$8,385
Pravastatin Sodium194$5,572
Colesevelam Hcl20$4,788
Losartan Potassium236$4,598
Ezetimibe48$3,611
Metformin Hcl ErMetformin Hcl155$2,908

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$840$94,76853 claims
Novo NordiskRybelsus, Ozempic$721$93,08751 claims
MerckJanuvia$236$58,32936 claims
Lilly USA, LLCTrulicity$878$55,42343 claims
PfizerEliquis$405$25,42119 claims
GSKTrelegy Ellipta$556$22,18927 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 655 internal medicine providers in Hawaii.

Other internal medicine in Aiea

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →